Recent Updates
Recently added Catalysts
NTHI Positive Sentiment

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NeOnc Technologies will hold an investor conference call on August 12, 2026, to discuss the topline results from its Phase 2a trial of NEO100. This trial targets recurrent IDH1-mutant high-grade glioma, showcasing the company's commitment to advancing its clinical-stage biopharmaceutical developments. The call aims to provide insights into the trial's findings and implications.

Market Sentiment Analysis

POSITIVE FACTORS

  • NeOnc Technologies is hosting an investor conference call.
  • The call will discuss topline results from a Phase 2a trial.
  • The focus is on NEO100 for treating recurrent IDH1-mutant high-grade glioma.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~0 mo
High dilution risk
Lead asset
Perillyl alcohol
Phase 1 · Glioblastoma Multiforme

Full Press Release Details

Call to be held Wednesday, August 12, 2026 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time CALABASAS, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel

Frequently Asked Questions

When is the NeOnc investor conference call?

The investor conference call is scheduled for August 12, 2026, at 5:30 a.m. PT.

What will be discussed in the investor call?

The call will discuss topline results from the Phase 2a trial of NEO100.

What is NEO100 targeting?

NEO100 is being developed for recurrent IDH1-mutant high-grade glioma.

ShareAdd on Google
Tags: NTHI Viatris Investor Conferences Healthcare NeOnc Technologies NEO100 Phase 2a IDH1-mutant glioma
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$0M liquidity · $2M/mo burn
~0 mo
High dilution risk
Lead asset
Perillyl alcoholPhase 1
Glioblastoma Multiforme →